Oren Hershkovitz

Presstek LLC supplies digital offset printing solutions for the printing and communications industries. Its solutions include commercial printers, in plants, packaging, digital, franchise printers, and mailing services. The firm also offers inkjet, commercial CTP, commercial plates, newspaper plates, workflow, conventional offset products, and finishing equipment. The company was founded by Lawrence A. Howard in 1987 and is headquartered in Hudson, CT.

The General Hospital Corp. provides healthcare services. It offers diagnostic and therapeutic are in every specialty and subspecialty of medicine and surgery. The firm's care center provides cancer, digestive disorders, heart disease, transplantation and vascular medicine services. The company was founded in 1811 and is headquartered in Boston, MA.

Flagship Pioneering (Flagship Pioneering) is a venture capital firm founded in 1982 by Ed M Kania and Noubar B Afeyan. The firm is headquartered in Cambridge, Massachusetts.

Part of Pluri, Inc., Pluristem Ltd. is an Israeli company that sources therapeutic cells from the placenta to create cell-based products for commercial use. The company is based in Haifa, Israel and was founded by Yoram Nathan Drucker. The company's patented and validated 3D cell expansion system is designed to mimic the human body, and its cell therapies have potentially groundbreaking applications for treating ischemia, damaged muscle, hematology deficiencies, and inflammation. Pluristem's method is uniquely accurate, cost-effective, and consistent from batch to batch. Pluristem was acquired by Pluri, Inc. on June 23, 2003.

The Institute of Human Virology (IHV) is a research institute located in Baltimore, MD, affiliated with the University of Maryland School of Medicine. The IHV is the first research institute in the US to link basic science, population studies, and clinical trials in an effort to develop new vaccines and treatments for chronic viral diseases such as HIV/AIDS, hepatitis C, hepatitis B, and human papillomavirus infection. The IHV serves approximately 5,000 patients through six Baltimore area clinics and more than 500,000 patients in seven African and two Caribbean nations. The IHV also provides compassionate cutting-edge care and specializes in the treatment of HIV/AIDS and other chronic viral diseases.

KAHR Medical Ltd. develops novel fusion protein pharmaceuticals for the treatment of cancer and autoimmune diseases. Its drug pipeline is built around the signal converter proteins a unique class of multi-functional therapeutic agents that convert signals sent from one cell to another. The firm?s therapeutic proteins integrate two functional units, enabling each one to elicit multiple cooperative functional endpoints. The company was founded by Mark L. Tykocinski in 2005 and is headquartered in Jerusalem, Israel.

Elastagen Pty Ltd. produces and develops synthetic human elastin for medical device applications. Its products include skin rejuvenation, scar remodeling, skin tissue repair, wound healing, surgical glues and sealants. The firm developed a Elastatherapy treatments which offer the chance to restore the levels of Elastin in human skin, with benefits anticipated in both medical dermatology and cosmetic applications. The company was founded by Anthony Weiss in 2003 and is headquartered in Sydney, Australia.

Celleron Therapeutics Ltd. is an oncology company based in Oxford, UK. The company has deep relationships with Oxford University and is located on the Oxford Science Park. Celleron is focused on developing new and innovative therapies to treat cancer, with a particular emphasis on clinical development. The British company is developing a novel group of clinical products, supported by predictive companion diagnostics, that act through defined molecular mechanisms to prevent cancer cell growth. Celleron's lead products are in clinical trials, supported by a biomarker platform that allows responsive patients to be identified. The company was founded in 2004 and is led by CEO Nick la Thangue.

Pavilion Data Systems, Inc. designs and develops NVMe-oF storage technologies. Its NVMe-over-Fabric Storage Array ingests, processes, stores, and serves an order of magnitude more data for massively-parallel, modern applications. The company was founded by Kiran Malwankar, V. R. Satish, and Sundar Kanthadai in 2014 and is headquartered in San Jose, CA.

X-Vax Technology, Inc. operates as a biotechnology company. The company was founded in 2015 and is headquartered in New York, NY.

Silicon Therapeutics LLC operates as an integrated computational drug discovery company that focuses on developing novel medicines for diseases. Its INSITE platform closely represents the dynamical nature of targets using all-atom simulations. The firm has offices in Boston and Shanghai. The company was founded by Lijun Sun, Peiqi Sun, Elliot L. Chaikof, and Finith Jernigan, III in 2016 and is headquartered in Boston, MA.

Viracta Subsidiary, Inc. engages in the development of proprietary viral gene activation therapy to address cancers associated with the Epstein-Barr virus. Its platform is designed as a targeted approach to treat a range of viral-associated cancers and other serious diseases. The company was founded by Ronald J. Berenson, Douglas V. Faller, George C. Hillman, Thalia Papayannopoulou, Susan P. Perrine, George Stamatoyannopoulos, and Robert Williams and is headquartered in Cardiff, CA.

Prolor Biotech Ltd. develops proprietary versions of already-approved therapeutic proteins. The private company is based in Nes Ziona, Israel.

Geneos Therapeutics, Inc. Develops and commercializes neo-antigen based personalized cancer therapies. The firm engages in developing personalized immunotherapies against tumor specific neoantigens which arise from gene mutations in cancerous cells. The company was founded by Niranjan Y. Sardesai in 2017 and is headquartered in Plymouth Meeting, PA.

Verimmune, Inc. is a company based in Washington that is dedicated to developing a first-in-class cancer immunotherapy called anti-tumor immune redirection (AIR). Verimmune's proprietary virus-inspired particle (VIP) technology platform redirects pre-existing pathogenic or childhood vaccine immune memory toward tumors. The American company's lead immuno-oncology product candidate, Veri-101, harnesses the cellular immune memory responses from prior cytomegalovirus (CMV) infection to fight cancer. This mechanism of action has the potential to redefine the treatment paradigm for patients with untreatable cancers or resistance to existing therapies. The company was founded in 1995 by John Troyer and Joshua Weiyuan Wang, with Joshua Weiyuan Wang serving as the CEO since then.

Aprinoia Therapeutics, Inc. operates as a global clinical-stage biopharmaceutical company. It develops imaging diagnostic tools, targeted therapy drugs, and other products. The company was founded in 2015 and is headquartered in Cambridge, MA.